Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1925-1935
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1925
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1925
Table 6 Comparison of the incidence of adverse events between the two groups during the treatment period
| Indicators | Observation group, n = 46 | Control group, n = 46 | χ2 | P value |
| Fever | 1 (2.317) | 1 (2.17) | ||
| Fatigue | 2 (4.35) | 1 (2.17) | ||
| Dizziness/headache | 2 (4.35) | 2 (4.35) | ||
| Decreased appetite | 2 (4.35) | 1 (2.17) | ||
| Diarrhea | 2 (4.35) | 1 (2.17) | ||
| Total incidence | 9 (19.57) | 7 (15.22) | 0.302 | 0.582 |
- Citation: Feng R, Cheng DX, Chen XC, Yang L, Wu H. Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1925-1935
- URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1925.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1925